ATE457307T1 - Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid - Google Patents

Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid

Info

Publication number
ATE457307T1
ATE457307T1 AT04759956T AT04759956T ATE457307T1 AT E457307 T1 ATE457307 T1 AT E457307T1 AT 04759956 T AT04759956 T AT 04759956T AT 04759956 T AT04759956 T AT 04759956T AT E457307 T1 ATE457307 T1 AT E457307T1
Authority
AT
Austria
Prior art keywords
amino
cyclobuten
dioxo
furanyl
hydroxy
Prior art date
Application number
AT04759956T
Other languages
English (en)
Inventor
Jianguo Yin
Xiaoyong Fu
Shuyi Zhang
Timothy Mcallister
Agnes Kim-Meade
Jason Winters
Anantha Sudhakar
Doris Schumacher
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE457307T1 publication Critical patent/ATE457307T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04759956T 2003-04-18 2004-04-16 Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid ATE457307T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46377303P 2003-04-18 2003-04-18
PCT/US2004/011882 WO2004094398A2 (en) 2003-04-18 2004-04-16 Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide

Publications (1)

Publication Number Publication Date
ATE457307T1 true ATE457307T1 (de) 2010-02-15

Family

ID=33310818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759956T ATE457307T1 (de) 2003-04-18 2004-04-16 Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid

Country Status (13)

Country Link
US (3) US7071342B2 (de)
EP (2) EP1615903B1 (de)
JP (2) JP4440917B2 (de)
CN (3) CN100448860C (de)
AR (1) AR044027A1 (de)
AT (1) ATE457307T1 (de)
CA (1) CA2522748C (de)
DE (1) DE602004025458D1 (de)
ES (1) ES2338657T3 (de)
MX (1) MXPA05011183A (de)
SG (1) SG167671A1 (de)
WO (1) WO2004094398A2 (de)
ZA (3) ZA200508129B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2554709C (en) * 2004-01-30 2011-11-15 Schering Corporation Crystalline polymorphs of a cxc-chemokine receptor ligand
US8183287B2 (en) 2006-06-12 2012-05-22 Schering Corporation Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
CA2692269A1 (en) * 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CA2694268A1 (en) * 2007-07-05 2009-01-08 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
EP2583960A4 (de) 2010-06-16 2015-07-15 Teijin Ltd Verfahren zur herstellung von zwischenprodukten für eine zyklische carbodiimidverbindung
WO2012147897A1 (ja) * 2011-04-25 2012-11-01 住友化学株式会社 アミン化合物の製造方法
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
US11052065B2 (en) 2017-09-27 2021-07-06 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
TWI849253B (zh) * 2019-11-11 2024-07-21 美商富曼西公司 用於製備3-溴-1- (3-氯吡啶-2-基) -1h-吡唑-5-羧酸乙酯的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791613A (en) * 1953-08-24 1957-05-07 Columbia Southern Chem Corp Metahaloaniline production using copper oxide-chromic oxide catalysts
CH691112A5 (de) 1995-03-14 2001-04-30 Sumitomo Chemical Co Verfahren zur Herstellung von Kristallen eines Schwefelsäuresalzes des 3-Amino-2-hydroxyacetophenons mit hoher Schüttdiche und verbesserten Fliesseigenschaften .
ZA991105B (en) * 1998-03-04 2000-02-11 Searle & Co Synthesis of chiral beta-amino acids.
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
IL156793A0 (en) * 2001-02-02 2004-02-08 Schering Corp 3,4-di-substituted cyclobutene-1,2-diones as cxc chemokine receptor antagonists
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
RU2344123C9 (ru) * 2001-04-16 2009-05-20 Шеринг Корпорейшн 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора
EP1485089B1 (de) * 2002-03-18 2013-04-17 Merck Sharp & Dohme Corp. Kombinationsbehandlungen für chemokine-bedingte erkrankungen
US12284102B2 (en) 2022-09-01 2025-04-22 Dell Products, L.P. Detection of collaboration sessions and other workloads in a heterogenous computing platform

Also Published As

Publication number Publication date
EP2168956B1 (de) 2013-03-20
EP1615903A2 (de) 2006-01-18
ES2338657T3 (es) 2010-05-11
CN1805947A (zh) 2006-07-19
WO2004094398A2 (en) 2004-11-04
EP2168956A2 (de) 2010-03-31
MXPA05011183A (es) 2005-12-14
JP4440917B2 (ja) 2010-03-24
SG167671A1 (en) 2011-01-28
WO2004094398A3 (en) 2005-03-03
ZA200800486B (en) 2009-07-29
US7910775B2 (en) 2011-03-22
US20040209946A1 (en) 2004-10-21
CN101514193A (zh) 2009-08-26
CN100448860C (zh) 2009-01-07
AR044027A1 (es) 2005-08-24
JP5202503B2 (ja) 2013-06-05
CN101514168B (zh) 2014-02-26
EP2168956A3 (de) 2010-07-14
EP1615903B1 (de) 2010-02-10
US7462740B2 (en) 2008-12-09
JP2006523616A (ja) 2006-10-19
DE602004025458D1 (de) 2010-03-25
US20060205961A1 (en) 2006-09-14
CN101514193B (zh) 2012-12-19
US7071342B2 (en) 2006-07-04
US20090048458A1 (en) 2009-02-19
ZA200508129B (en) 2008-04-30
EP2168956B8 (de) 2013-05-01
HK1078315A1 (en) 2006-03-10
CN101514168A (zh) 2009-08-26
CA2522748A1 (en) 2004-11-04
ZA200800487B (en) 2009-08-26
JP2010053139A (ja) 2010-03-11
CA2522748C (en) 2011-06-28

Similar Documents

Publication Publication Date Title
DE60102356D1 (de) Asymmetrische synthese von pregabalin
DE602004025458D1 (de) SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID
BRPI0415710A (pt) formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
ATE337090T1 (de) Synthese von molekularsiebkatalysatoren
EP1634645A4 (de) Katalysator für die acrylnitril-synthese
ATE458726T1 (de) Exo- und diastereoselektive synthese von himbacin-analoga
FR2834890B1 (fr) Composition pharmaceutique orodispersible d'agomelatine
ATE353878T1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
FR2829139B1 (fr) Synthese d'elastomeres trans-1,4-polybutadiene, a haute teneur en motifs trans
ATE381263T1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5 thiazolcarboxamide enthalten
WO1999055687A3 (en) Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
HRP20040920A2 (en) Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
DE69901024D1 (de) Asymmetrischen synthese von 2-aryl-1-substituierten butan-2,3-diolen
ITMI20020991A0 (it) Procedimento per la sintesi del modafinil
EP1809616A4 (de) Synthese von aminosäure-n-carboxyanhydriden
AU2002305242A1 (en) Synthesis of carbamate through low pressure heterogeneous oxidative carbonylation of amines
EP1534783A4 (de) Synthese von cis-diolen aus arylsilanen
DE50205590D1 (de) Ummantelung von leiterbahnen
DK1644340T3 (da) N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer
ATE248804T1 (de) Synthese von chiralen beta-aminosäuren
BR0317956A (pt) sìntese de (r) e (s)-aminocarnitina e derivados das mesmas a partir de ácido d e l-aspártico
EP1391198A4 (de) Neuer sphingolipid-synthese-hemmer
PE20050674A1 (es) Derivados de cromano
DE60213541D1 (de) Discodermolid-Analoga und ihre pharmazeutische Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties